EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieÄquivalenzstudieOpen access · CC BY 4.0

A double‐blind, randomized, placebo‐controlled study assessing the impact of probiotic supplementation on the symptoms of irritable bowel syndrome in females

B H Mullish iD, D R Michael, M Dabcheva, T S Webberley, N Coates, D A John, D Wang, Y Luo, S F Plummer, J R Marchesi

Neurogastroenterology & Motility · 2024-04 · 36 (4)

DOI: 10.1111/nmo.14751 ↗

At a glance

Randomisierte kontrollierte Studie in Neurogastroenterology & Motility, published online on 2024-01-29. Written by B H Mullish and 9 co-authors. Institution: Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK. Major MEDLINE topics: Irritable Bowel Syndrome, Probiotics. Cited 29 times so far (Crossref); 68 references. The full text is freely available (open access, CC BY 4.0). Funded by: Cultech Ltd.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

A previous exploratory study demonstrated the ability of the Lab4 probiotic to alleviate the symptoms of IBS, and post hoc data analysis indicated greatest improvements in the female subgroup. The aim of this study is to confirm the impact of this multistrain probiotic on IBS symptom severity in females.

Methods

An 8‐week, single‐center, randomized, double‐blinded, placebo‐controlled, superiority study in 70 females with Rome IV‐diagnosed irritable bowel syndrome (IBS) receiving the Lab4 probiotic (25 billion colony‐forming units) daily or a matched placebo. Changes from baseline in the IBS‐symptom severity score (IBS‐SSS), daily bowel habits, anxiety, depression, IBS‐related control, and avoidance behavior, executive function, and the fecal microbiota composition were assessed. The study was prospectively registered: ISRCTN 14866272 (registration date 20/07/22). Key Results At the end of the study, there were significant between‐group reductions in IBS‐SSS (−85.0, p < 0.0001), anxiety and depression scores (−1.9, p = 0.0002 and −2.4, p < 0.0001, respectively), and the IBS‐related control and avoidance behavior score (−7.5, p = 0.0002), all favoring the probiotic group. A higher proportion of the participants in the probiotic group had normal stool form ( p = 0.0106) and/or fewer defecations with loose stool form ( p = 0.0311). There was little impact on the overall diversity of the fecal microbiota but there were significant differences in Roseburia , Holdemanella , Blautia , Agathobacter , Ruminococcus , Prevotella , Bacteroides , and Anaerostipes between the probiotic and placebo groups at the end of the study. Conclusions & Inferences Daily supplementation with this probiotic may represent an option to be considered in the management of IBS.

Subjects

MeSH terms (MEDLINE)

Irritable Bowel SyndromeProbioticsHumansFemaleTreatment OutcomeDiarrheaAnxietyDouble-Blind Method

Author keywords

IBSbowel habitmicrobiotaprobiotic

Authors and institutions

  • Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.
  • Cultech Limited, Port Talbot, UK.
  • Clinical Research Unit, MC Comac Medical, Sofia, Bulgaria.
  • Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
  • Mailman School of Public Health, Columbia University Medical Centre, New York, New York, USA.

ORCID profiles: B H Mullish

Funding

  • Cultech Ltd

Cite

APA

Mullish, B. H., Michael, D. R., Dabcheva, M., Webberley, T. S., Coates, N., John, D. A., Wang, D., Luo, Y., Plummer, S. F., & Marchesi, J. R. (2024). A double‐blind, randomized, placebo‐controlled study assessing the impact of probiotic supplementation on the symptoms of irritable bowel syndrome in females. Neurogastroenterology & Motility, 36(4). https://doi.org/10.1111/nmo.14751

Vancouver

Mullish BH, Michael DR, Dabcheva M, Webberley TS, Coates N, John DA, et al. A double‐blind, randomized, placebo‐controlled study assessing the impact of probiotic supplementation on the symptoms of irritable bowel syndrome in females. Neurogastroenterology & Motility. 2024;36(4). doi:10.1111/nmo.14751

BibTeX
@article{Mullish2024,
  author = {Mullish, B H and Michael, D R and Dabcheva, M and Webberley, T S and Coates, N and John, D A and Wang, D and Luo, Y and Plummer, S F and Marchesi, J R},
  title = {A double‐blind, randomized, placebo‐controlled study assessing the impact of probiotic supplementation on the symptoms of irritable bowel syndrome in females},
  journal = {Neurogastroenterology & Motility},
  year = {2024},
  volume = {36},
  number = {4},
  doi = {10.1111/nmo.14751}
}
Start for free →